| Study Period | 2019 - 2030 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2025 - 2030 |
| CAGR | 6.50 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | High |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Allergy Immunotherapy Market Analysis
The Allergy Immunotherapy Market is expected to register a CAGR of 6.5% during the forecast period.
The COVID-19 pandemic adversely affected communities, industries, businesses, and lives across the world. Many companies received approval for their vaccines against the SARS-CoV-2 virus and still focusing their research and development on the development of therapeutics against COVID-19. However, allergy patients needed continuous treatment and medication supply owing to which healthcare professionals continued to give treatments or treatment advice during the pandemic. For instance, according to the study published in February 2021, by Allergy, Asthma & Immunology Research, it was recommended that allergic patients who were suffering from asthma, rhinitis, atopic dermatitis, or chronic urticaria should continue to receive maintenance therapy in a well-controlled manner during the pandemic. Furthermore, according to the study published in February 2021, by Current Allergy and Asthma Reports, to continue treatment of allergic rhinitis, remote health care tools for first visits or monitored patients were implemented during pandemic and it also suggested to continue treatment in case of uninfected patients or recovered from COVID-19 infection and interrupt in case of positive or suspected SARS-CoV-2 infection. Therefore, such instances indicate that the market continue to grow even after the pandemic.
The increasing burden of various types of allergies and launch of new sublingual immunotherapies in emerging economies are the major drivers for the market. The increasing burden of various types of allergies is one of the key drivers for the market. For instance, according to the journal published by the SingleCare in January 2022, more than 50.0 million Americans suffers from some type of allergy every year. It also reported that allergies are the sixth leading chronic illness in the United States. A survey was also conducted by SingleCare in 2021, which reported that 82.0% of respondents with allergies reported these allergies affects the quality of life in the United States. The survey result also showed that 14.0% of the respondents reported hospitalizations due to an allergic reaction. Therefore, such an increasing cases of allergies is anticipated to propel the demand for allergy immunotherapy thereby propelling the market growth over the forecast period.
Furthermore, the increasing focus of the companies on research and development activities to develop novel dallergy immunotherapy to cater to high unmet medical needs is highly impacting the market's growth. In February 2023, Nectar Life Sciences launched of its innovative comprehensive allergy care platform, Nectar. The first product offering from the company's allergy treatment program, Nectar Allergy Drops, are personalized, industry-proven sublingual immunotherapy drops to provide life-long relief from allergies by treating the root cause.
However, lack of awareness about allergy and treatments is expected to hinder the market growth over the forecast period.
Allergy Immunotherapy Market Trends
Subcutaneous Immunotherapy (SCIT) is Expected to Witness Growth Over the Forecast Period
Subcutaneous immunotherapy (SCIT), is the most commonly used and most effective form of allergy immunotherapy and it is the only treatment available that actually changes the immune system, making it possible to prevent the development of new allergies and asthma. SCIT is a unique therapy for allergic disease as it provides symptomatic relief while modifying allergic disease by targeting the underlying immunological mechanism. Its efficacy and safety have been demonstrated in the treatment of asthma, allergic rhinitis/rhinoconjunctivitis, and hypersensitivity to stinging insects in multiple controlled clinical trials. SCIT is administered by injection, and refers to what is commonly known as an 'allergy shot'. It is the standard medication for allergen desensitization and provides symptomatic relief for patients with allergic rhinitis and asthma.
The high efficacy and cost-effectiveness of SCIT is the major driver for the segment. For instance, as per the study published in August 2021, by the Journal of Allergy and Clinical Immunology: In Practice, SCIT is much more effective than SLIT drops or tablets in controlling symptoms of allergic rhinitis. Therefore, high efficacy of SLIT indicates that the demand for the product is anticiapted to increase, thereby surging the segment growth over the forecast period.
In June 2021, Stallergenes Greer announced that Alustal, its subcutaneous allergen immunotherapy (SCIT) solution, was available in Italy and Spain following the full resumption of SCIT production in Antony (France).
Understand The Key Trends Shaping This Market
Download PDF
North America is Expected to Hold the Largest Market Share over the Forecast Period
North America is expected to dominate the overall allergy immunotherapy market, over the forecast period. The growth is due to factors such as increasing cases of allergies and increasing awareness of allergy treatment. For instance, according to the report published by International Food Information Council in May 2022, in the United States, about 32.0 million people have reported having food allergies, and each year around 200,000 people seek emergency medical care due to food allergies. It also reported that food allergies were common among youths, with about one in every 13 children being diagnosed with a food allergy in the United States and around 40.0% of children with food allergies being allergic to more than one food. Such instances are anticipated to propel the demand for allergy immunotherapy in this region.
Key product launches, high concentration of market players or manufacturer's presence, and acquisition & partnerships among major players, and increasing cases of allergies in the United States are some of the factors driving the growth of the allergy immunotherapy market in the country. For instance, in January 2023, ALK announced that the US FDA approved ODACTRA (House Dust Mite Allergen Extract) Tablet for Sublingual Use for the treatment of house dust mite (HDM)-induced allergic rhinitis in persons ages 12 through 17.
Therefore, owing to the aforesaid factors the growth of the studied market is anticipated in the North America Region.
Get Analysis on Important Geographic Markets
Download PDF
Allergy Immunotherapy Industry Overview
The market studied is a consolidated market owing to the presence of a few major market players. The competitive landscape includes an analysis of a few international as well as regional companies which hold the market shares and are well known including Aimmune Therapeutics, Hollister Allergy, Leti Pharma, Merck KGaA (Allergopharma), Stallergenes Greer, Allergy Therapeutics, ALK-Abello A/S, HAL Allergy Group, Biomay AG, and Circassia among others.
Allergy Immunotherapy Market Leaders
-
Merck KGaA (Allergopharma)
-
Jubliant Pharma (Hollister Allergy)
-
Leti Pharma
-
Stallergenes Greer
-
ALK-Abello A/S
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competiters?
Download PDF
Allergy Immunotherapy Market News
- In July 2022, Stallergenes Greer, a global healthcare company that specializes in allergen immunotherapy (AIT), announced the positive data related to the significant benefit of sublingual liquid allergen immunotherapy treatment (AIT) on the onset and worsening of asthma in patients with allergic rhinitis.
- In March 2022, Aravax Pty Ltd announced the opening of investigational new drug (IND) application for Phase 2 clinical trials of PVX108, a next-generation immunotherapy for the treatment of peanut allergy
Allergy Immunotherapy Industry Segmentation
As per the scope of this report, allergy immunotherapies are a preventive treatment for allergic reactions to substances. It involves gradually increasing doses of the substance, or allergen, to which the person is allergic. The allergy immunotherapy market is segmented by type of immunotherapy (subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT)), allergy type (allergic rhinitis, asthma, food allergy, and others), and geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| By Type of Immunotherapy | Subcutaneous Immunotherapy (SCIT) | |
| Sublingual Immunotherapy (SLIT) | ||
| By Allergy Type | Allergic Rhinitis | |
| Asthma | ||
| Food Allergy | ||
| Others | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Need A Different Region or Segment?
Customize Now
Allergy Immunotherapy Market Research FAQs
What is the current Global Allergy Immunotherapy Market size?
The Global Allergy Immunotherapy Market is projected to register a CAGR of 6.5% during the forecast period (2025-2030)
Who are the key players in Global Allergy Immunotherapy Market?
Merck KGaA (Allergopharma), Jubliant Pharma (Hollister Allergy), Leti Pharma, Stallergenes Greer and ALK-Abello A/S are the major companies operating in the Global Allergy Immunotherapy Market.
Which is the fastest growing region in Global Allergy Immunotherapy Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Global Allergy Immunotherapy Market?
In 2025, the North America accounts for the largest market share in Global Allergy Immunotherapy Market.
What years does this Global Allergy Immunotherapy Market cover?
The report covers the Global Allergy Immunotherapy Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Allergy Immunotherapy Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
Allergy Immunotherapy Industry Report
Statistics for the 2025 Allergy Immunotherapy market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Allergy Immunotherapy analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
